Q&A: Bris­tol My­er­s' Kris­ten Hege on cell ther­a­py, can­cer pa­tients and men­tor­ing the next gen­er­a­tion

Kris­ten Hege leads Bris­tol My­ers Squibb’s ear­ly on­col­o­gy dis­cov­ery pro­gram car­ry­ing on from the same work at Cel­gene, which was ac­quired by BMS in 2019. She’s known for her ear­ly work in CAR-T, hav­ing pi­o­neered the first CAR-T cell tri­al for sol­id tu­mors more than 25 years ago.

How­ev­er, the em­i­nent physi­cian-sci­en­tist is more than just a drug de­vel­op­er mas­ter­mind. She’s al­so a prac­tic­ing physi­cian, moth­er to two young women, an avid back­pack­er and in­ter­sect­ing all those in­ter­ests — a cham­pi­on of young women and peo­ple of col­or in STEM and life sci­ences.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER